AKR1B10 colloidal gold detection kit and application thereof
The AKR1B10 qualitative kit developed through the colloidal gold method uses the dual antibody sandwich method to achieve fast and sensitive AKR1B10 detection, solving the problems of inconvenient detection time and equipment requirements in the prior art, and providing an economical and practical solution, suitable for Early diagnosis and disease screening.
Patent Information
- Application Number
- CN202411093174.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-09
- Publication Date
- 2024-11-29
AI Technical Summary
The existing AKR1B10 detection method requires expensive large-scale instruments and equipment and professional technical personnel, and the detection time and site are inconvenient, and there is a lack of fast and economical colloidal gold detection methods.
A qualitative kit was developed using the colloidal gold method to detect the AKR1B10 protein content in human serum by using the dual antibody sandwich method, including colloidal gold binding pad, chromatography membrane, water absorption pad and PVC base plate, and the mouse anti-AKR1B10 monoclonal antibody and The specific binding of rabbit anti-AKR1B10 polyclonal antibody showed red precipitation bands for qualitative judgment.
It realizes fast, sensitive, easy to operate and economical AKR1B10 testing, fills the market gap, has high clinical value and market application value, and is suitable for early diagnosis and disease screening.
Smart Images

Figure BDA0004987143360000061 
Figure BDA0004987143360000071 
Figure BDA0004987143360000081
Abstract
Description
Technical Field
[0001] The invention relates to the field of biological immunochromatographic detection methods, and in particular to a qualitative kit for detecting the content of aldehyde-keto reductase 1B10 (AKR1B10) protein by a colloidal gold method and an application thereof. Background Art
[0002] The liver is an important metabolic and detoxification organ in the human body, and is involved in the biological transformation and metabolism of the human body. Liver diseases are mainly divided into hepatitis, fatty liver, alcoholic liver, schistosomiasis liver, cirrhosis, and liver cancer according to the development process. Hepatitis patients suffer from liver inflammation and other diseases due to factors such as alcohol, viruses, and drugs. Surveys show that only about 1 / 10 of hepatitis B patients detect and receive treatment in the early stages of the disease, causing persistent damage to the liver, leading to activation of hepatic stellate cells (HSCs) and excessive deposition of extracellular matrix. Chronic hepatitis patients gradually develop liver fibrosis, cirrhosis, and liver cancer. Liver diseases have become an important factor threatening human health due to their high incidence, high secrecy, and rapid disease development. Therefore, the development of a rapid diagnostic method for early detection, efficacy judgment, prognosis evaluation, or recurrence monitoring is of great value for the diagnosis and treatment of liver diseases.
[0003] Aldo-Keto Reductase 1B10 (AKR1B10) is a human nicotinamide adenine dinucleotide phosphate (NADPH)-dependent reductase belonging to the AKR 1B subfamily with a molecular weight of 36.02 kDa. AKR1B10 plays a key role in various tumors such as HCC and various diseases of the liver and gastrointestinal tract, including but not limited to lipogenesis, oxidative stress, detoxification of cytotoxic reactive carbonyls and regulation of S1P. It is a new tissue and serum marker for tumors and benign diseases, and has very good application value in disease occurrence, diagnosis, treatment, and prognosis.
[0004] At present, the detection methods of AKR1B10 are magnetic microparticle chemiluminescence and time-resolved immunofluorescence analysis. These methods are quantitative detection methods with the advantages of high accuracy, high sensitivity, and good repeatability. However, they need to be equipped with expensive large-scale instruments and equipment, and general laboratories need to be equipped with professional detection technicians. Compared with colloidal gold detection, they do not have advantages in detection time and required venues. The application of colloidal gold technology as one of the immunochromatographic methodologies has been well developed and promoted. It has the advantages of being fast, economical, accurate, and simple, and has been widely used in timely detection of disease markers and family self-examination. At present, such products have not been developed on the market. Therefore, the development of a new colloidal gold rapid detection kit for aldehyde-keto reductase 1B10 (AKR1B10) is of great clinical value and market application value. Summary of the invention
[0005] In view of the above problems, we provide a qualitative kit for detecting the content of aldehyde-keto reductase 1B10 (AKR1B10) protein by colloidal gold method and its application. In order to solve the problems existing in the above prior art, the kit prepared by the present invention has the advantages of rapid reaction, high sensitivity, simple detection operation, economical and practical, etc.
[0006] The invention discloses a qualitative kit for detecting the content of aldehyde-keto reductase 1B10 (AKR1B10) protein by a colloidal gold method, and adopts a double antibody sandwich method to detect the AKR1B10 protein in human serum. The kit comprises the following components: a sample pad, a colloidal gold binding pad, a chromatographic membrane, a water-absorbing pad and a PVC bottom plate.
[0007] Among them, the colloidal gold pad is coated with mouse anti-AKR1B10 monoclonal antibody, and the chromatographic membrane is coated with a detection line (T line) of anti-AKR1B10 antibody. The serum sample of the subject is dropped on the sample pad, and the sample moves under capillary action. If the aldehyde-keto reductase 1B10 (AKR1B10) protein is present in the sample, it will bind to the colloidal gold-labeled antibody on the colloidal gold binding pad, continue to move forward, and bind to another specific antibody at the detection line. Since the colloidal gold-labeled antibody aggregates on the T line, the colloidal gold precipitates and focuses here and appears red. Qualitative judgment can be made by naked eye.
[0008] The chromatographic membrane is also coated with a quality control line (C line) of goat anti-mouse IgG. If the subject has bands at both the test line and the quality control line after the test, it means the test is positive. If no band is observed at the test line, it is negative. If there are no bands on both the test line and the quality control line, or if there are bands on the test line but not on the quality control line, it means there is a problem with the kit and it should be replaced.
[0009] The colloidal gold pad is coated with mouse anti-AKR1B10 monoclonal antibody, the chromatographic membrane is coated with an anti-AKR1B10 antibody detection line and a goat anti-mouse IgG quality control line, wherein the mouse anti-AKR1B10 monoclonal antibody is prepared by hybridoma cell technology, the detection antibody is the AKR1B10 polyclonal antibody obtained by immunizing rabbits with AKR1B10 protein, and the goat anti-mouse IgG antibody is a commercial antibody that recognizes the Fc fragment of the antibody.
[0010] Preferably, the concentration of the two mouse anti-AKR1B10 monoclonal antibodies coated with colloidal gold is 20 μg / mL; the two antibodies are 4E11 and 8D09. The two preferred specific monoclonal antibodies were cloned and sequenced, and the sequences are as follows:
[0011] A monoclonal antibody named 4E11, whose heavy chain variable region consists of 118 amino acid residues, and whose light chain variable region consists of 112 amino acid residues; a monoclonal antibody named 8D09, whose heavy chain variable region consists of 126 amino acid residues, and whose light chain variable region consists of 117 amino acid residues:
[0012] VH(4E11):ESIVNTISCLTSSPGLPSEQLSHGYYCEKFELLEWIGVDCYFSMRGQGTA YNKIYSYDNTFPNAIETELTHRWVMDTLTLICCCQTSFKSYVWPGSEPEPEEKWIWCCDKS DSGLQVT.
[0013] VL(4E11):IYYCSLGEIKNHRNSTSELTFKSYVVLNIPVQKEWLIYPVLLYCCDRRMT NLFFSEWDKSIYRSMNTAKSREEGIWMDVSVRAPLASSDLGVVHACKTIKYLIESYYDEPA A.
[0014] VH(8D09):LVELGSGRAGSNLGTYGNYVETLNIQHIRTSGSGVASEFMVKQLGIRTWIFKSYNPGGSNWVKIHSGVSCGNYVVCM CMVAYMELFSDNTNLGTDQIKVSEKFKSHGKRLLISNIKVSGSWGQVVK.
[0015] VL(8D09): SLFYGAYFPPWLLIVSATTTKIHWNGSNNYMTMTKHSGRSKTKQIEWF RFMCKIKIKGIYKSMEWWNPAGSELFTILIYNVSSGSALGFYGSAYSCKSFYGRAAIEWTTR NYLGTMT.
[0016] Preferably, the concentration of the rabbit anti-AKR1B10 polyclonal antibody coated on the test line is 1 mg / mL.
[0017] Preferably, the concentration of the goat anti-mouse IgG coated on the quality control line is 1 mg / mL.
[0018] The present invention provides the use of the kit in preparing a detection reagent for screening and diagnosing tumors. Preferably, the kit is used to adopt a double antibody sandwich immunoassay: the aldehyde-keto reductase 1B10 protein in the sample to be tested is combined with the colloidal gold-coated antibody, and then moves to the detection line position and then combines with the detection antibody, and the colloidal gold gathers on the detection line to develop color;
[0019] Specifically, the tumor is liver cancer, lung cancer, breast cancer, pancreatic cancer, bladder cancer, bile duct cancer, gastrointestinal cancer, etc., as well as hepatitis, cirrhosis, fatty liver, alcoholic liver, non-alcoholic fatty liver, schistosomiasis liver, ulcerative colitis, Crohn's disease;
[0020] Specifically, the samples to be tested include serum, plasma, whole blood, urine, saliva, stool extract, oral or human tissue extract.
[0021] The present invention also discloses a preparation method of the colloidal gold immunochromatographic detection card of AKR1B10, comprising the following steps: preparing a mixed solution of colloidal gold-4E11 and colloidal gold-8D09, fixing the gold label solution on a colloidal gold pad; fixing rabbit anti-aldehyde-keto reductase 1B10 polyclonal antibody and goat anti-mouse IgG as detection line and quality control line antibodies on a chromatography membrane NC membrane, attaching a binding pad to the front end of the chromatography membrane NC, attaching a sample pad to the front end of the binding pad, and finally attaching the front end of an absorbent paper to the rear end of the chromatography membrane, and attaching the other end to the end of a PVC board, thereby completing the assembly of the test kit.
[0022] More specifically, the following steps are included:
[0023] 1. Prepare 0.01% aqueous solution of HauC14 with purified water, take 100ml and heat to boiling. Add 1mL 1% trisodium citrate, and observe obvious color change. When it turns to bright red, stop heating, cool to room temperature, dilute to 100mL, and seal for later use;
[0024] 2. Take 0.1 mg of each 4E11 and 8D09 monoclonal antibodies, add 5 ml of the above colloidal gold solution (PH 8.0), mix for 1 hour, and mix in a ratio of 1:1 to obtain a colloidal gold-4E11 and colloidal gold-8D09 mixed solution;
[0025] 3. Add 0.5 ml of 10% BSA and 0.2 ml of 5% PEG (20000) to the colloidal gold labeled antibody mixture, mix well and block for 30 minutes.
[0026] 4. Centrifuge at 10,000 rpm in a high-speed refrigerated centrifuge for 15 minutes, discard the supernatant, add 10 ml of PBS buffer to resuspend, centrifuge for 15 minutes and discard the supernatant, repeat twice, and resuspend the precipitate with dilution buffer.
[0027] 5. Soak the colloidal gold pad in the pretreatment buffer for 10 minutes, drain for 10 minutes, dry in an oven at 37 degrees, cut off the edge of about 0.5 cm, and seal it to store at 4 degrees.
[0028] 6. Adjust the gold spray instrument parameters to 10PSI, 5ul / cm, fix the gold label solution on the colloidal gold pad, dry at 37 degrees, and seal for storage.
[0029] 7. Dilute rabbit anti-AKR1B10 polyclonal antibody and goat anti-mouse IgG to 1 mg / ml in gold-labeled buffer as detection line and quality control line antibodies; adjust the gold-spraying instrument parameters to 10 PSI, 1 ul / cm film drawing, place the NC film in an oven to dry for 2 hours, seal and store, take out and put into a sealed bag for later use;
[0030] 8. Assembling the test kit: Stick the NC membrane to the PVC bottom plate, stick the colloidal gold pad to the front end of the NC membrane, covering an area of 2mm, then stick the sample pad to the front end of the colloidal gold pad, covering an area of 2mm, stick the front end of the 180mm×100mm absorbent paper to the back end of the NC membrane, covering an area of 2mm, cut the assembled test strips into strips of 5mm in width and 18mm in length, and put them into the card shell to obtain the AKR1B10 rapid detection kit.
[0031] Furthermore, the gold-labeled buffer is: 0.01M buffer, pH 7.0-8.0, comprising the following ingredients: 0.5%-2.0% BSA, 1.0%-2.0% sucrose, 0.5%-2.0% glycine, 1.0%-2.0% mannitol, 0.5%-2.0% gelatin, 0.01%-1.0% Tween 20, and 0.01%-0.10% Pclin 300.
[0032] Preferably, the gold-labeled buffer is: 0.01 M buffer, pH 8.0, 2% BSA, 1% sucrose, 0.5% glycine, 1% mannitol, 0.5% gelatin, 0.05% Tween 20, 0.05% Pclin 300.
[0033] Furthermore, the colloidal gold pad is soaked in a colloidal gold pretreatment solution, wherein the pretreatment solution comprises 0.01M phosphate buffer, 1.0% to 2% BSA, 0.05% to 1% Tween-20, 0.05% to 0.1% Pclin 300, 1.0% to 2% gelatin, and 0.1-1% PVP-10, pH 8.0±0.1;
[0034] Preferably, the colloidal gold pad is soaked in a colloidal gold pretreatment solution, wherein the pretreatment solution comprises 0.01M phosphate buffer, 1.0% BSA, 0.05% Tween-20, 0.05% Pclin 300, 1.0% gelatin, 0.5% PVP-10, pH 8.0±0.1;
[0035] The beneficial effects of the present invention are:
[0036] 1. We have developed a new colloidal gold rapid detection kit for aldehyde-keto reductase 1B10 (AKR1B10), which fills the gap in the market and greatly solves the clinical patients' needs for rapid disease detection and screening. It has high clinical value and market application value.
[0037] 2. Due to the low content of aldehyde-keto reductase 1B10 (AKR1B10) in human blood, only at the pg level, and the inherent detection sensitivity of colloidal gold technology itself compared to other methodological barriers, colloidal gold test strips prepared in a conventional manner are difficult to meet clinical detection needs. The present invention screened high-specificity cell lines through hybridoma cell technology, prepared 6 highly active mouse anti-monoclonal antibodies through mouse ascites preparation and protein G affinity chromatography purification, and conducted Elisa addition experimental analysis on the recognition epitopes of 4 of the monoclonal antibodies, selected monoclonal antibodies that specifically bind to different epitopes of the antigen, and proved through experiments that colloidal gold coated with two different antibodies can improve the ability to capture the antigen to be detected in the sample, and at the same time, the detection line antibody (T line) selects rabbit anti-AKR1B10 polyclonal antibodies that can recognize multiple sites of the antigen, avoiding competitive binding between antibodies to the same site of the antigen, which can effectively improve the sensitivity of detection.
[0038] 3. The process optimization was carried out on the step of coating the colloidal gold pad with the gold-labeled antibody, and the colloidal gold pad was pretreated. First, the gold-labeled pad pretreatment solution of the present invention adopts a low concentration of buffer ion strength to avoid salt ion crystallization blocking the gold pad micropores as much as possible; the macromolecular substance polyvinyl pyrrolidone (PVP-10) plays a skeleton role as a macromolecular substance for the uniform distribution of colloidal gold after drying, effectively preventing the gold pad from hardening and effectively controlling the antibody release rate and ratio; BSA and gelatin block the gold pad to avoid non-specific binding of the labeled antibody, and at the same time play a role in protecting the protein. The addition of the surfactant Tween-20 at an appropriate concentration allows the substance to be tested to react fully after binding with the gold-labeled antibody and release and move to the NC membrane evenly and slowly; furthermore, the gold-labeled antibody complex diluent was optimized, and protective proteins, carbohydrates, amino acids, surfactants, etc. were added to the buffer to effectively ensure the stability of the gold-labeled antibody. In short, the kit prepared by this method has the advantages of stable performance, high sensitivity, and strong specificity. BRIEF DESCRIPTION OF THE DRAWINGS
[0039] Figure 1 It is a schematic diagram of the structure of the kit of the present invention;
[0040] Figure 2 It is a guide diagram for determining the detection results of the kit of the present invention. DETAILED DESCRIPTION
[0041] The present invention is further illustrated by the detailed description of specific embodiments below, but it is not intended to limit the present invention and is merely an example. In the following embodiments, unless otherwise specified, all are conventional methods.
[0042] Example 1 Preparation of mouse anti-AKR1B10 monoclonal antibody hybridoma cell line and antibody:
[0043] 1. Animal immunization
[0044] The immune-enhancing Freund's adjuvant was mixed with the recombinant AKR1B10 protein in the same proportion and injected intraperitoneally into four 6-8 week-old Balb / c mice (purchased from Hunan Slake Jingda Experimental Animal Co., Ltd.) using a primary-boost immunization strategy. The immunization dose was 30 μg / mouse, divided into three immunizations with an interval of 2 weeks.
[0045] 2. Cell Fusion
[0046] Three days after the third immunization, the mice were killed by cervical dislocation, spleen cells were collected, mixed with SP2 / 0 cells at a ratio of 10:1, 1 ml of 50% polyethylene glycol (PEG4000) was added and the mixture was promoted in a 37°C water bath. After 40 ml of M1640 culture medium was taken to terminate the fusion, the mixture was centrifuged, and hybridoma cells were selected and cultured with HAT medium. The growth of hybridoma cells was observed under a microscope.
[0047] 3. Cell Screening
[0048] Dilute the AKR1B10 recombinant antigen to 200 ng / ml and coat the Elisa plate. Add 200 ul of the supernatant from each culture well, incubate, wash, add HRP-labeled goat anti-mouse IgG antibody, develop color with TMB, terminate the reaction with 2M sulfuric acid, and screen for hybridoma cells that produce positive antibodies.
[0049] 4. Subcloning of positive cell lines
[0050] The limiting dilution method was used for cloning culture, and three subclonings were performed. After cloning, 6 hybridoma cell lines with high activity and stable secretion of anti-AKR1B10 antibodies were obtained, which were named 5G04, 4E11, 4C08, 8D09, 3E07, and 5G12 respectively.
[0051] 5. Antibody Preparation
[0052] The monoclonal antibody was obtained by the ascites preparation method. The above 6 positive hybridoma cell lines were expanded and cultured, and the logarithmic phase cells were collected and injected into the peritoneal cavity of mice. The ascites was collected and the antibody was purified by affinity chromatography. The antibody concentration after purification ranged from 2.0 to 5.0 mg / ml.
[0053] Example 2 Epitope analysis and antibody selection of mouse anti-AKR1B10 monoclonal antibody:
[0054] 1. After the accelerated stability study of the six monoclonal antibodies obtained in Example 1, the 3E07 and 5G12 antibodies with poor stability were excluded, and the remaining four antibodies were subjected to ELISA addition experiments to analyze the differences in binding antigen epitopes between different antibodies. 10ug / ml AKR1B10 antigen was coated, and the saturation concentration of each antibody was determined. Each single antibody reaction was used as the control group, and the two saturated concentrations of the tested monoclonal antibodies were mixed in equal amounts as the test group. The OD490 of each group was read by indirect method, and the test was repeated 5 times to calculate the coefficient of variation (CV value), and the addition coefficient (AI) was calculated. The formula is AI=2A 1+2 / (A1+A2)*100%, with 50% as the boundary, AI>50% indicates that the two antibodies target different antigenic epitopes; AI<50% indicates that the two antibodies target similar antigenic epitopes. The results are shown in Table 1. The results show that the AI values of the 5G04+8D09 and 4E11+8D09 monoclonal antibody combinations are greater than 50%, indicating that the antigenic epitopes recognized by the 5G04, 4E11 and 8D09 monoclonal antibodies are different.
[0055] Table 1 Epitope analysis of anti-AKR1B10 monoclonal antibodies
[0056]
[0057] Example 3 Preparation and performance comparison of colloidal gold kit for rapid detection of aldehyde-keto reductase 1B10 (AKR1B10):
[0058] Step 1: Take 0.1 mg of each 4E11 and 8D09 monoclonal antibodies, coat them with 5 ml of colloidal gold solution, mix them in a ratio of 1:1, and record them as gold labeling solution A; take 0.1 mg of each 5G04 and 8D09 monoclonal antibodies, coat them with 5 ml of colloidal gold solution, mix them in a ratio of 1:1, and record them as gold labeling solution B; take 0.2 mg of each 4E11, 8D09 and 5G04 monoclonal antibodies, coat them with 10 ml of colloidal gold solution, and record them as gold labeling solutions C, D, and E;
[0059] Step 2: Prepare colloidal gold test strips A to E by sealing, gold spraying, film drawing, etc. according to the preparation method described in the invention content.
[0060] Step 3: Dilute the AKR1B10 standard with negative human serum to standard solutions with concentrations of 100pg / ml, 300pg / ml, 500pg / ml, and 1000pg / ml, respectively. The negative solution is the negative serum without the AKR1B10 standard; then drop 80μL of the standard solutions of different concentrations into the assembled colloidal gold detection card, observe and record the results. The detection sensitivity of groups A to E was analyzed, and the results are shown in Table 2. The results show that the kit of group A has the best sensitivity (300pg / ml), that is, it is determined that the method of using 4E11 and 8D09 monoclonal antibodies against different antigen epitopes of AKR1B10 to jointly coat colloidal gold can significantly improve the detection sensitivity of colloidal gold.
[0061] Table 2 Analysis of detection sensitivity of different antibody groups
[0062]
[0063] Comparative Example 1 Preparation of colloidal gold kit for rapid detection of aldehyde-keto reductase 1B10 (AKR1B10):
[0064] The difference from the preparation method of test strip A in Example 3 is that the complex coupled with colloidal gold and mouse anti-AKR1B10 monoclonal antibody is diluted with 0.01M phosphate buffer at pH 8.0±0.1; the colloidal gold pad is pretreated with 0.01M phosphate buffer at pH 8.0±0.1, and the other preparation methods and steps are the same as in Example 3.
[0065] Example 4 Method for determining the results of the colloidal gold-labeled anti-AKR1B10 antibody kit
[0066] The results of the AKR1B10 rapid test kit are judged as follows: Figure 2 As shown in Figure 2, when both the C line (quality control band) and the T line (detection band) are colored, the sample being tested contains AKR1B10 (corresponding to Figure 2 When the C line (control band) is colored, but the T line (test band) is not colored, it means that the sample does not contain or contains AKR1B10 below the sensitivity level (corresponding to Figure 2 If the C line (control band) does not show color, the test result is invalid regardless of whether the T line (test band) shows color or not (corresponding to Figure 2 (C, D).
[0067] Example 5 Performance test experiment of AKR1B10 colloidal gold rapid detection kit
[0068] 1. Kit repeatability test
[0069] Three batches of aldehyde-keto reductase 1B10 (AKR1B10) detection kit (colloidal gold method) prepared by the test strip A method in Example 3 were used to detect 200 pg / ml, 300 pg / ml, and 1000 pg / ml of AKR1B10 quality control products, respectively, and each was measured 6 times to observe the repeatability of the kit. The results are shown in Table 2 below, and the results show that the intra-batch and inter-batch repeatability of the kit is 100%, and the false positive rate and false negative rate are both 0.
[0070] Table 3 Repeatability test results of AKR1B10 colloidal gold detection kit
[0071]
[0072] 2. Real-time stability test of the kit
[0073] The test strip A in Example 3 and the aldehyde-keto reductase 1B10 (AKR1B10) detection kit of Comparative Example 1 were sealed and stored at 4°C and room temperature (about 25°C), and the stability of the test strip A and the kit of Comparative Example 2 at different temperatures was observed. The test results are shown in Table 3 below, and the results show that the test strip A can be stored for 18 months at 4°C and 12 months at room temperature, while the kit of Comparative Example 1 can only be stored for 5 months at 4°C and 1 month at room temperature.
[0074] Table 4 Stability test results of AKR1B10 colloidal gold detection kit prepared by different methods
[0075]
[0076]
[0077] Example 6 Clinical Validation of AKR1B10 Colloidal Gold Rapid Detection Kit
[0078] In this experiment, a total of 104 clinical samples of liver cancer and 140 normal samples were collected, totaling 244 samples. The sensitivity and specificity of the result judgment were confirmed using the test strip A aldehyde-keto reductase 1B10 (AKR1B10) detection kit in Example 3. The conformity of the positive and negative samples determined by the gold standard with the gold standard diagnosis at a critical value of 300pg / ml was evaluated. The results are shown in Table 2 below, which show that the sensitivity of the kit is 90 / 104=86.54%; the specificity is 131 / 140=93.57%, and the total conformity rate is (131+90) / 244=90.57%. The results are shown in Table 4.
[0079] Table 5 Clinical validation experimental results of AKR1B10 colloidal gold detection kit
[0080]
[0081] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.
Claims
1. A kit for rapid detection of aldehyde-keto reductase 1B10, the kit comprising a sample pad, a colloidal gold binding pad, a chromatography membrane, a water-absorbing pad and a PVC bottom plate, wherein the sample pad, the colloidal gold binding pad, the chromatography membrane and the water-absorbing pad are sequentially overlapped on the PVC bottom plate, characterized in that: The colloidal gold pad is coated with mouse anti-aldehyde-keto reductase 1B10 monoclonal antibody, and the chromatographic membrane is coated with a detection line of the anti-aldehyde-keto reductase 1B10 antibody and a quality control line of goat anti-mouse IgG.
2. The kit according to claim 1, characterized in that The colloidal gold and the mouse anti-aldehyde-keto reductase 1B10 monoclonal antibody coupled complex are solidified on the colloidal gold binding pad, and the concentration of the mouse anti-aldehyde-keto reductase 1B10 monoclonal antibody coupled complex is 15-25 μg / mL (preferably 20 μg / mL).
3. The kit according to claim 1, characterized in that The colloidal gold pad is coated with two mouse anti-aldehyde-keto reductase 1B10 monoclonal antibodies 4E11 and 8D09, which are prepared by hybridoma cell technology and recognize different antigen epitopes.
4. The kit according to claim 3, characterized in that The method for coating the colloidal gold pad with two mouse anti-aldehyde-keto reductase 1B10 monoclonal antibodies is that colloidal gold is coated with 4E11 and 8D09 monoclonal antibodies respectively, and preferably the two are mixed in a ratio of 1:1 and fixed on the colloidal gold pad.
5. The colloidal gold detection kit according to claim 3, characterized in that: The colloidal gold pad is pretreated with colloidal gold pad buffer solution, wherein the pretreatment solution includes: 0.01M phosphate buffer solution, containing 1.0%-2% BSA, 0.05%-1% Tween-20, 0.05%-0.1% Pclin 300, 1.0%-2% gelatin, 0.1-1% PVP-10, pH 8.0±0.
1.
6. The colloidal gold detection kit according to claim 3, characterized in that: The colloidal gold coupling complex is diluted with a gold-labeled buffer, and the buffer is one of a PBS buffer, a tris-HCl buffer, and a citric acid buffer.
7. The kit according to claim 3, characterized in that The gold-labeled buffer solution has a concentration of 0.01 M buffer solution, a pH of 7.0-8.0, and contains the following ingredients: 0.5%-2.0% BSA, 1.0%-2.0% sucrose, 0.5%-2.0% glycine, 1.0%-2.0% mannitol, 0.5%-2.0% gelatin, 0.01%-1.0% Tween 20, and 0.01%-0.10% Pclin 300.
8. Use of the kit according to any one of claims 1 to 7 in the preparation of a detection reagent for screening and diagnosing tumors, preferably, the kit according to any one of claims 1 to 7 adopts a double antibody sandwich immunoassay: the aldehyde-keto reductase 1B10 protein in the sample to be tested is combined with the colloidal gold-coated antibody, and then moves to the detection line position and then combines with the detection antibody, and the colloidal gold aggregates at the detection line to develop color; Specifically, the tumor is liver cancer, lung cancer, breast cancer, pancreatic cancer, bladder cancer, bile duct cancer, gastrointestinal cancer, etc., as well as hepatitis, cirrhosis, fatty liver, alcoholic liver, non-alcoholic fatty liver, schistosomiasis liver, ulcerative colitis, Crohn's disease; Specifically, the samples to be tested include serum, plasma, whole blood, urine, saliva, stool extract, oral or human tissue extract.
9. A method for preparing a kit for rapid detection of aldehyde-keto reductase 1B10 according to any one of claims 3 to 7, characterized in that: The following steps are involved: Prepare a mixed solution of colloidal gold-4E11 and colloidal gold-8D09, and fix the gold label solution on the colloidal gold pad; fix rabbit anti-aldehyde-keto reductase 1B10 polyclonal antibody and goat anti-mouse IgG as detection line and quality control line antibodies on the chromatographic membrane NC membrane, stick the conjugate pad to the front end of the chromatographic membrane NC, then stick the sample pad to the front end of the conjugate pad, and finally stick the front end of the absorbent paper to the rear end of the chromatographic membrane, and stick the other end to the end of the PVC board, and the kit is assembled.
10. The preparation method according to claim 9, characterized in that: The steps include: (1) Prepare 0.01% aqueous solution of HauC14 with purified water, take 100 ml and heat to boiling; add 1 mL 1% trisodium citrate, and observe obvious color change. When it turns to bright red, stop heating, cool to room temperature, make up to 100 mL, and seal for later use; (2) Take 0.1 mg of each of 4E11 and 8D09 monoclonal antibodies, add 5 ml of the above colloidal gold solution (pH 8.0), mix for 1 h, and mix in a 1:1 ratio to obtain a colloidal gold-4E11 and colloidal gold-8D09 mixed solution; (3) Add 0.5 ml of 10% BSA and 0.2 ml of 5% PEG (20000) to the colloidal gold-labeled antibody mixture, mix well and block for 30 minutes; (4) Centrifuge at 10,000 rpm for 15 min in a high-speed refrigerated centrifuge, discard the supernatant, add 10 ml of gold label buffer and resuspend, centrifuge for 15 min and discard the supernatant, repeat twice, and resuspend the precipitate with dilution buffer; (5) Soak the colloidal gold pad in the pretreatment buffer for 10 min, drain for 10 min, dry in a 37°C oven, cut off the edge of about 0.5 cm, and seal and store at 4°C; (6) Adjust the gold spraying instrument parameters to 10 PSI, 5 ul / cm, fix the gold label solution on the colloidal gold pad, dry at 37°C, and seal for storage; (7) Dilute rabbit anti-AKR1B10 polyclonal antibody and goat anti-mouse IgG to 1 mg / ml in gold-labeled buffer as detection line and quality control line antibodies; adjust the gold-spraying instrument parameters to 10 PSI, 1 ul / cm for film drawing, place the chromatographic membrane NC membrane in an oven to dry for 2 hours, seal it for storage, take it out and put it in a sealed bag for later use; (8) Assembly of the kit: Attach the conjugate pad to the front end of the chromatographic membrane NC, then attach the sample pad to the front end of the conjugate pad, and finally attach the front end of the absorbent paper to the rear end of the chromatographic membrane and the other end to the end of the PVC board. The kit is now assembled.
